J&J (JNJ) COVID Booster Jab Shows Its Effectiveness Against Omicron


Johnson & johnson JNJ announced preliminary data from the phase IIIb Sisonke 2 study, which evaluated the booster dose of its COVID-19 vaccine (Ad26.COV2.S) among healthcare workers in South Africa who received the The company’s main vaccine schedule for COVID-19.

During the study period, that is, from mid-November to mid-December, J&J noted that the frequency of the Omicron variant increased from 82% to 98% in South Africa.

The Sisonke 2 study (n = 227,310) demonstrated that homologous booster injection reduced the risk of hospitalization from COVID-19 among healthcare workers in South Africa after Omicron became the dominant variant. In fact, the booster dose increased the vaccine’s effectiveness over time to 85% against hospitalization.

Please note that the homologous booster was administered six to nine months after the primary regimen of the J&J COVID vaccine.

J&J also reported data from a separate analysis of the immune response to different vaccine regimens. The analysis evaluated the administration of a heterologous booster dose of the J&J booster dose versus a homologous booster dose in individuals who initially received the main regimen in two doses of J&J. Pfizer PFE and BioNTechBNTX mRNA vaccine, BNT162b2.

Neutralizing antibodies and CD8 + T cells were higher after a booster dose of J & J’s vaccine. A heterologous booster injection of J & J’s COVID vaccine generated a 41-fold increase in neutralizing antibodies four weeks after the boost against the Omicron variant, while the homologous booster injection of BNT162b2 generated a 17-fold increase.

J & J’s heterologous COVID vaccine booster also generated a five-fold increase in CD8 + T cells in two weeks after the Omicron booster dose compared to a 1.4-fold increase generated by Pfizer / BioNTech’s homologous BNT162b2 booster .

According to J&J, CD8 + T cells generated from its COVID vaccine may be the reason for the high level of efficacy against hospitalization in the Sisonke 2 study, since the Omicron variant showed the ability to evade neutralizing antibodies.

J&J shares are up 9.5% so far this year compared to the industry’s 21.8% increase.

Image source: Zacks Investment Research

We note that BNT162b2 is marketed in the United States under the trade name Comirnaty. Earlier this month, Pfizer and BioNTech announced data from a pseudovirus neutralization test, which demonstrated that three doses of Comirnaty neutralize the Omicron variant.

Pfizer / BioNTech stated that administration of the third dose of Comirnaty provided a level of protection against the Omicron variant that was comparable to the level achieved against the wild-type virus after the initial two-dose regimen. If a specific Omicron booster is needed, the two companies plan to deliver one by March 2021.

In addition to the boosters developed by J&J and Pfizer / BioNTech, Modern MRNA is also evaluating its own COVID-19 mRNA vaccine, mRNA-1273, against the Omicron variant.

Moderna is also evaluating its multivalent booster and Omicron-specific booster candidates in phase II / III studies. Earlier this month, Moderna announced preliminary data from a pseudovirus neutralization titer assay study, which demonstrated that its COVID-19 vaccine booster significantly increased neutralizing antibody levels against the Omicron variant.

Moderna continues to develop an Omicron-specific booster candidate in case it becomes necessary in the future amid the growing infection cases from Omicron. The Omicron-specific booster candidate will enter a clinical study in early 2022.

Earlier this month, the US Centers for Disease Control and Prevention (“CDC”) recommended the use of mRNA-based COVID-19 vaccines – Comirnaty and mRNA-1273 – or their booster dose compared to J & J’s single injection COVID-19 vaccine.

The CDC has said that J & J’s vaccine or its booster dose should only be used when mRNA-based vaccines are contraindicated for a person or are inaccessible.

Following the recommendation, J&J defended his COVID vaccine by stating that he remains confident in the vaccine’s overall positive benefit-risk profile. The company believes that its single dose administration, along with its ease of storage and transport, makes the vaccine a better option.

Johnson & Johnson Award

Johnson & Johnson Award

Johnson & Johnson Award | Johnson & Johnson quote

Zack Rank

Johnson & Johnson currently holds a Zacks Rank # 3 (Hold). You can see The full list of Zacks # 1 Rank (Strong Buy) stocks today here.

Zacks Top 10 stocks for 2022

In addition to the investment ideas discussed above, would you like to know our top 10 picks for all of 2022?

From its creation in 2012 until November, the Top 10 Zacks stocks gained an impressive + 962.5% versus + 329.4% for the S&P 500. Now our research director combs through the 4,000 companies covered by the Zacks rankings to select the top 10 tickers to buy and hold . Don’t miss your chance to participate in these actions when they release on January 3.

Be the first in the new Top 10 stocks >>

Click to get this free report

Johnson & Johnson (JNJ): Free Stock Analysis Report

Pfizer Inc. (PFE): Free Inventory Analysis Report

Moderna, Inc. (MRNA): Free Stock Analysis Report

ADR Sponsored by BioNTech SE (BNTX): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks investment research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Comments are closed.